Skip to main content
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2009 Nov 27;5(1):86. doi: 10.1208/pt050112

Preparation and physicochemical characterization of 5 niclosamide solvates and 1 hemisolvate

Elsa C van Tonder 1,, Mabatane D Mahlatji 2, Sarel F Malan 3, Wilna Liebenberg 1, Mino R Caira 4, Mingna Song 5, Melgardt M de Villiers 5,
PMCID: PMC2784863  PMID: 15198533

Abstract

The purpose of the study was to characterize the physicochemical, structural, and spectral properties of the 1∶1 niclosamide and methanol, diethyl ether, dimethyl sulfoxide, N,N' dimethylformamide, and tetrahydrofuran solvates and the 2∶1 niclosamide and tetraethylene glycol hemisolvate prepared by recrystallization from these organic solvents. Structural, spectral, and thermal analysis results confirmed the presence of the solvents and differences in the structural properties of these solvates. In addition, differences in the activation energy of desolvation, batch solution calorimetry, and the aqueous solubility at 25°C, 24 hours, showed the stability of the solvates to be in the order: anhydrate > diethyl ether solvate > tetraethylene glycol hemisolvate > methanol solvate > dimethyl sulfoxide solvate > N,N' dimethylformamide solvate. The intrinsic and powder dissolution rates of the solvates were in the order: anhydrate > diethyl ether solvate > tetraethylene glycol hemisolvate > N,N' dimethylformamide solvate > methanol solvate > dimethyl sulfoxide solvate. Although these nonaqueous solvates had higher solubility and dissolution rates than the monohydrous forms, they were unstable in aqueous media and rapidly transformed to one of the monohydrous forms.

Keywords: niclosamide, solvates, solubility, physical stability

Full Text

The Full Text of this article is available as a PDF (787.1 KB).

References

  • 1.Reynolds JEF, editor. Martindale the Extra Pharmacopoeia. 30th ed. London, UK: The Pharmaceutical Press; 1993. [Google Scholar]
  • 2.World Health Organization.Niclosamide Technical. Full specification WHO/SMT/6.R1. Geneva, Switzerland: World Health Organization; Revised 10 December 1999.
  • 3.Budavari S, editor. The Merck Index. 11th ed. Rahway, NY: Merck; 1989. [Google Scholar]
  • 4.van Tonder EC, de Villiers MM, Lötter AP, Caira MR, Liebenberg W. Correlation between hydrate formation and the physical instability of suspensions with different niclosamide crystal forms. Pharm Ind. 1998;60:722–725. [Google Scholar]
  • 5.Otsuka M, Kato F, Matsuda Y. Physicochemical stability of cimetidine amorphous forms estimated by isothemal microcalorimetry.AAPS PharmSciTech. 2002;3(4): Article 30. Available at: http://www.pharmscitech.org. [DOI] [PMC free article] [PubMed]
  • 6.Otsuka M, Ishii M, Matsuda Y. Effect of surface modification on hydration kinetics of carbamazepine anhydrate using isothermal microcalorimetry.AAPS PharmSciTech. 2003;4(1): Article 5. Available at: http://www.pharm scitech.org. [DOI] [PMC free article] [PubMed]
  • 7.Caira MR, Nassimbeni LR. Phase transformations in inclusion compounds, kinetics and thermodynamics of enclathration. In: Attwood JL, Davies JED, Macnicol DD, Vögtle F, editors. Comprehensive Supramolecular Chemistry. New York, NY: Pergamon; 2004. pp. 132–145. [Google Scholar]
  • 8.van Tonder EC, Maleka TSP, Liebenberg W, Song M, Wurster DE, de Villiers MM. Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm. 2004;269:417–432. doi: 10.1016/j.ijpharm.2003.09.035. [DOI] [PubMed] [Google Scholar]
  • 9.Caira MR, van Tonder EC, de Villiers MM, Lötter AP. Diverse modes of solvent inclusion in crystalline pseudopolymorphs of the anthelmintic drug niclosamide. J Inc Phenom Mol Recog Chem. 1998;31:1–16. doi: 10.1023/A:1007931314609. [DOI] [Google Scholar]
  • 10.Ford JL, Timmins P. Thermal Analysis in the Characterization of Pharmaceutical Solids. Chichester, UK: Ellis Horwood; 1989. [Google Scholar]
  • 11.Singh P, Desai SJ, Flanagan DR, Simonelli AP, Higuchi WI. Mechanistic study of the influence of micelle solubilization and hydrodynamic factors on the dissolution rate of solid drugs. J Pharm Sci. 1968;57:959–965. doi: 10.1002/jps.2600570608. [DOI] [PubMed] [Google Scholar]
  • 12.Lötter AP, Flanagan DR, Palepu NR, Guillory JK. A simple reproducible method for determining dissolution rates of hydrophobic powders. Pharm Technol. 1983;7:55–66. [Google Scholar]
  • 13.United States Pharmacopoeial Convention.United States Pharmacopoeia. USP 25: NF 20 Rockville, MD: United States Pharmacopoeial Convention; 2002.
  • 14.Guillory JK, Erb DM. Using solution calorimetry to quantitate binary mixtures of the three crystalline forms of sulfamethoxazole. Pharm Manuf. 1985;2:29–33. [Google Scholar]
  • 15.Botha SA, Caira MR, Guillory JK, Lötter AP. Physical characterization of the methanol solvate of urapidil. J Pharm Sci. 1992;78:28–34. doi: 10.1002/jps.2600780109. [DOI] [PubMed] [Google Scholar]
  • 16.Moffat MA, Jackson JV, Moss MS, Widdop B, editors. Clarke's Isolation and Identification of Drugs in Pharmaceuticals, Body Fluids, and Post Mortem Materials. 2nd ed. London, UK: Pharmaceutical Press; 1986. [Google Scholar]
  • 17.Kosheleva LI, Bekhli AF. Polymorphic modifications of phenasal and their IR spectra. Khimiko-Farmatsevticheskii Zhurnal. 1974;8:57–60. [Google Scholar]
  • 18.Kosheleva LI, Shumakovish IE, Bekhli AF. IR spectra and structure of substituted salicylanilides. Zhurnal Obshchei Khimii. 1975;45:407–411. [Google Scholar]
  • 19.Wall LA, Flynn JH. Quick, direct method for determination of activation energy from thermogravimetric data. Pol Lett. 1966;4:323–328. doi: 10.1002/pol.1966.110040504. [DOI] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES